Codify Therapeutics - About the company
Codify Therapeutics is a funded company based in London (United Kingdom), founded in 2022. It operates as a Developer of therapeutics exploiting alternative RNA splicing. The company has 400 active competitors, including 151 funded and 107 that have exited. Its top competitors include companies like BioNTech, ADMA Biologics and Nimbus Therapeutics.
Company Details
Developer of therapeutics exploiting alternative RNA splicing. The company is leveraging alternative splicing to discover transformational medicines that address unmet medical needs and improve the lives of patients.
Key Metrics
Founded Year
2022
Location
London, United Kingdom
Stage
Funding Raised
Investors
Ranked
389th among 400 active competitors
Sign up to download Codify Therapeutics' company profile
Codify Therapeutics's funding and investors
Codify Therapeutics is a funded company. Codify Therapeutics has 1 institutional investor.
View details of Codify Therapeutics's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Codify Therapeutics's Competitors and alternates
Top competitors of Codify Therapeutics include BioNTech, ADMA Biologics and Nimbus Therapeutics. Here is the list of Top 10 competitors of Codify Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 72/100 | ||
2nd | ADMA Biologics 2005, Ramsey (United States), Public | Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases | $17.6M | 71/100 | |
3rd |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
4th | Apellis Pharmaceuticals 2008, Crestwood (United States), Public | Developer of therapeutics for the treatment of rare diseases | $213M | 68/100 | |
5th | PureTech Health 2001, Boston (United States), Public | Developer of immunotherapeutics for multiple diseases | $107M | 67/100 | |
6th |  Cabaletta Bio 2017, Radnor (United States), Public | Developer of CAAR T cells for B cell-mediated autoimmune diseases | $88.3M | 67/100 | |
7th |  Vera Therapeutics 2016, San Francisco (United States), Public | Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases | $197M | 66/100 | |
8th |  Astria 2008, Boston (United States), Acquired | Developer of therapeutics for rare diseases | $117M | 65/100 | |
9th |  Vividion Therapeutics 2016, Oceanside (United States), Acquired | Pioneering chemoproteomics and covalent chemistry for precision therapeutics targeting undruggable disease drivers | $271M | 61/100 | |
10th |  Vedanta Biosciences 2010, Cambridge (United States), Series E | Developer of therapeutics to treat infectious diseases | $350M | 65/100 | |
389th | Codify Therapeutics 2022, London (United Kingdom), Funding Raised | Developer of therapeutics exploiting alternative RNA splicing | - | 22/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Codify Therapeutics's competitors? Click here to see the top ones
Codify Therapeutics's Investments and acquisitions
Codify Therapeutics has made no investments or acquisitions yet.
Reports related to Codify Therapeutics
Here is the latest report on Codify Therapeutics's sector:
Are you a Founder ?
FAQs about Codify Therapeutics
Explore our recently published companies
- Hix - Unfunded company
- Approvednetworks - Unfunded company
- Molexces - Unfunded company
- Bpdoxs - Patiala based, 2023 founded, Unfunded company
- Platestahl - Germany based, Unfunded company
- Aspecto - Germany based, 2000 founded, Unfunded company
